These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25270597)

  • 1. Should off-label drugs be included as comparators in pharmacoeconomic studies?
    Walton SM; Schumock GT
    Pharmacoeconomics; 2014 Nov; 32(11):1035-7. PubMed ID: 25270597
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical pricing conundrum: time to get rid of it?
    Garattini L; Padula A
    Eur J Health Econ; 2018 Nov; 19(8):1035-1038. PubMed ID: 30030646
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug utilisation studies as tools in health economics.
    Sacristán JA; Soto J
    Pharmacoeconomics; 1994 Apr; 5(4):299-312. PubMed ID: 10147239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of pharmacoeconomics in prescribing research. Part 2: cost-minimization analysis--when are two therapies equal?
    Newby D; Hill S
    J Clin Pharm Ther; 2003 Apr; 28(2):145-50. PubMed ID: 12713612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action.
    Al-Jazairi AS; Al-Qadheeb NS; Ajlan A
    Ann Saudi Med; 2011; 31(4):335-41. PubMed ID: 21808106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic considerations in anaesthetic use.
    Suttner S; Kumle B; Boldt J
    Expert Opin Pharmacother; 2002 Sep; 3(9):1267-72. PubMed ID: 12186619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State Remedies For Costly Prescription Drugs.
    Cauchi R
    NCSL Legisbrief; 2018 Aug; 26(29):1-2. PubMed ID: 30199170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic considerations for allergen immunotherapy.
    Bernstein JA
    Clin Allergy Immunol; 2004; 18():151-64. PubMed ID: 15042914
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of blood product use and costs with use of 3-factor versus 4-factor prothrombin complex concentrate for off-label indications.
    DeAngelo J; Jarrell DH; Cosgrove R; Camamo J; Edwards CJ; Patanwala AE
    Am J Health Syst Pharm; 2018 Aug; 75(15):1103-1109. PubMed ID: 29941507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PhRMA sues on 340B orphans.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):17. PubMed ID: 24340726
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitfalls associated with commonly used methods for pharmacoeconomic analyses.
    Klepser DG
    Pharmacotherapy; 2002 Feb; 22(2 Pt 2):35S-38S. PubMed ID: 11837545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing medicines: theory and practice, challenges and opportunities.
    Gregson N; Sparrowhawk K; Mauskopf J; Paul J
    Nat Rev Drug Discov; 2005 Feb; 4(2):121-30. PubMed ID: 15688076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis to illustrate the impact of cost definitions on results, interpretations and comparability of pharmacoeconomic studies in the US.
    Tunis SL
    Pharmacoeconomics; 2009; 27(9):735-44. PubMed ID: 19757867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of future costs in health economic analysis publications: current situation and recommendations for the future.
    Gros B; Soto Álvarez J; Ángel Casado M
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):465-9. PubMed ID: 25737028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data.
    Desgagné A; Castilloux AM; Angers JF; LeLorier J
    Pharmacoeconomics; 1998 May; 13(5 Pt 1):487-97. PubMed ID: 10180748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of perspective in pharmacoeconomic analyses.
    Oderda GM
    J Pain Palliat Care Pharmacother; 2002; 16(4):65-9. PubMed ID: 14635827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics: an emerging discipline.
    Letizia C
    Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The need for pharmacoeconomic studies of pharmacy services.
    Rascati KL; Moczygemba LR
    Clin Ther; 2007 Jul; 29(7):1488-90. PubMed ID: 17825700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.